Shots:
- Merus to receive $40M up front, $20M as an equity investment, ~$540M as development & commercial milestones making it a total of $1.6B for three products, along with royalties, following the commercialization of therapies
- Merus will lead discovery and early-stage research activities while Loxo Oncology at Lilly will be responsible for additional research, development, and commercialization activities
- The collaboration leverages Merus’ Biclonics platform along with the scientific & rational drug design expertise of Loxo Oncology at Lilly to research and develop up to three CD3-engaging T-cell redirecting bispecific Ab therapies
Click here to read full press release/ article | Ref: PRNewswire | Image: Bilaterals.org
The post Lilly and Merus Collaborate to Discover Novel T-Cell Re-Directing Bispecific Antibodies first appeared on PharmaShots.
